Efficacy of Curcuma longa in treatment of postprandial distress syndrome: an open-label randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180131001

Enrollment

Registered

2018-01-31

Start date

2018-03-05

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postprandial distress syndrome Postprandial distress syndrome&#44

Interventions

Curcuma longa capsule (250mg) 1 cap po tid pc,Curcuma longa capsule (250mg) 2 cap po tid pc,simethicone (80 mg) 1 tab chew po tid pc

Experimental Drug,Experimental Drug,Active Comparator Drug

750 mg of Curcuma longa,1500 mg of Curcuma longa,240 mg simethicone

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: - Patients with PDS of functional dyspepsia according to ROME IV criteria including uninvestigated dyspepsia - No alarm features - Discontinued all GI medications for 1 week

Exclusion criteria

Exclusion criteria: - Drugs allergy (simethicone and/or Curcuma longa) - Pregnancy/lactation - History of gastric malignancy - History of gallstone or biliary obstruction

Design outcomes

Primary

Measure	Time frame
Global overall symptom scale of dyspepsia 4 weeks 7-point Likert scale	—

Secondary

Measure	Time frame
Rate of recurrence 6 weeks record in diary ,time of recurrence 6 weeks record in diary ,side effects 4 weeks record in diary	—

Contacts

Public ContactNicharat Sawangroj

Khon Kaen hospital

n.sawangroj@gmail.com080-412-8920

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Efficacy of Curcuma longa in treatment of postprandial distress syndrome: an open&#45;label randomized controlled trial